SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, March 9th, 2023 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2022 and to highlight recent corporate progress.
Conference Call & Webcast Details
| Date: | Thursday, March 9th, 2023 |
| Time: | 4:30 p.m. EST |
| Live call: | Register here for dial-in number and pin |
| Webcast: | https://edge.media-server.com/mmc/p/wi7rgr4x |
Participants may access a live webcast of the call on the Investors page of the Bionano website. To participate via telephone, please register in advance at this link.
Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionanogenomics.com/ for at least 30 days.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.63 |
| Daily Change: | 0.03 4.22 |
| Daily Volume: | 1,021,509 |
| Market Cap: | US$43.330M |
July 23, 2024 July 08, 2024 July 05, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
